RILPIVIRINE

SynDRA canonical compound SYN0005524 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx
Primary target(s)	CYP2C19 \| CYP3A5 \| NR1I2 \| SCN10A
Mechanism of action	non-nucleoside reverse transcriptase inhibitor
Indication	human immunodeficiency virus (HIV-1)
Disease area	infectious disease

All known targets

Non-Nucleoside Reverse Transcriptase Inhibitors
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Nucleic Acid Synthesis Inhibitors
Reverse Transcriptase Inhibitors

edurant
rilpivirine hydrochloride
rilpivirine HCl
Rilpivirina
R-278474
R278474
TMC-278
TMC278
Edurant
Rekambys
Rilpivirine component of cabenuva
UNII-FI96A8X663
4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile
CHEBI:68606
FI96A8X663
R 278474
4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
(E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile
(E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile
W-202888
RPV
Mu O-conotoxin
TMC 278
CABENUVA COMPONENT RILPIVIRINE
rilpivirinum
HCl, Rilpivirine
RefChem:55980
Hydrochloride, Rilpivirine
DTXCID90120680
J05AG05
Rilpivirine free base
MFCD11046372
Rilpivirine [INN]
Rilpivirine Z-Isomer HCl
Rilpivirine [USAN:INN]
HSDB 8153
Edurant(TM)
Rekambys (TN)